Impact of Dapagliflozin on Mortality in Patients With Heart Failure and Reduced Ejection Fraction: A Meta-analysis.

Document Type


Publication Date



The DAPA-HF trial1 demonstrated that dapagliflozin reduced the risk of worsening heart failure and death in patients with heart failure and reduced ejection fraction (HFrEF). In the EMPEROR-Reduced trial,2 empagliflozin also reduced the composite primary endpoint but failed to show any significant reduction of cardiac death or all-cause death. This may be explained by the fact that EMPEROR-Reduced was underpowered regarding cardiac death or all-cause death. A meta-analysis3 of these 2 trials revealed that the estimated treatment effect of cardiac death and all-cause death was modestly significant. In view of this, it would be necessary to revisit the mortality benefits of dapagliflozin, as DAPA-HF was not powered for the mortality endpoints either. Here, we undertook a meta-analysis of DAPAHF and the HFrEF subgroup of DECLARE-TIMI 584 to evaluate the mortality benefits of dapagliflozin in HFrEF patients.

Publication Title

American Journal of Therapeutics

PubMed ID



This article was published in American Journal of Therapeutics.

The published version is available at

Copyright © 2021 Wolters Kluwer Health, Inc.

This document is currently not available here.